Technical Analysis for NKTR - Nektar Therapeutics

Grade Last Price % Change Price Change
grade A 54.87 -0.62% -0.34
NKTR closed down 0.62 percent on Tuesday, December 12, 2017, on 68 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Up
See historical NKTR trend table...

Date Alert Name Type % Chg
Dec 12 Inside Day Range Contraction 0.00%
Dec 12 Wide Bands Range Expansion 0.00%
Dec 12 Overbought Stochastic Strength 0.00%
Dec 11 New 52 Week Closing High Bullish -0.62%
Dec 11 New 52 Week High Other -0.62%
Dec 11 Stochastic Reached Overbought Other -0.62%
Dec 11 Wide Bands Range Expansion -0.62%
Dec 11 Overbought Stochastic Strength -0.62%
Dec 8 NR7 Range Contraction 1.67%
Dec 8 Inside Day Range Contraction 1.67%

Older signals for NKTR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates in various therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company's drug candidates in clinical development stage comprise naloxegol, an opioid antagonist that is in Phase 3 clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase 2 clinical trail to treat gram-negative pneumonias; NKTR-181, a mu-opioid analgesic molecule, which is in Phase 2 clinical trail for chronic pain; and NKTR-192 that is in Phase 1 to treat acute pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase 3 clinical trial for the treatment of metastatic breast cancer; in Phase 2 clinical trail for ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 for the treatment of chronic pain; NKTR-171 to treat neuropathic pain; and NKTR-214, a cytokine immunostimulatory therapy for the treatment of oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. Further, it has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, MAP Pharmaceuticals, Merck, Pfizer, Roche, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.
Is NKTR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 56.35
52 Week Low 11.41
Average Volume 2,374,022
200-Day Moving Average 23.7077
50-Day Moving Average 35.285
20-Day Moving Average 50.4025
10-Day Moving Average 53.269
Average True Range 2.8752
ADX 63.78
+DI 33.19
-DI 8.57
Chandelier Exit (Long, 3 ATRs ) 47.7244
Chandelier Exit (Short, 3 ATRs ) 39.9956
Upper Bollinger Band 59.0184
Lower Bollinger Band 41.7866
Percent B (%b) 0.76
BandWidth 34.188384
MACD Line 5.7217
MACD Signal Line 6.1772
MACD Histogram -0.4555
Fundamentals Value
Market Cap 8.58 Billion
Num Shares 156 Million
EPS -1.40
Price-to-Earnings (P/E) Ratio -39.19
Price-to-Sales 27.79
Price-to-Book 1075.45
PEG Ratio 3.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 57.87
Resistance 3 (R3) 58.00 57.12 57.37
Resistance 2 (R2) 57.12 56.36 57.06 57.20
Resistance 1 (R1) 56.00 55.89 55.56 55.87 57.04
Pivot Point 55.12 55.12 54.91 55.06 55.12
Support 1 (S1) 54.00 54.36 53.56 53.87 52.70
Support 2 (S2) 53.12 53.89 53.06 52.54
Support 3 (S3) 52.00 53.12 52.37
Support 4 (S4) 51.87